Sign Out
Asthma: Symbicort Rapihaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short acting β2 adrenoceptor agonists; or patients already adequately controlled on both inhaled corticosteroids and long acting β2 adrenoceptor agonists.
Note: Symbicort Rapihaler (80/4.5 micrograms/actuation) is not appropriate in patients with severe asthma.
Chronic Obstructive Pulmonary Disease (COPD): Symbicort Rapihaler is indicated in the regular treatment of patients with moderate to severe COPD, with frequent symptoms and a history of exacerbations.
Note: Symbicort Rapihaler (80/4.5 micrograms/actuation) is not appropriate in patients with COPD.
Continue with Google